Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Flavio Augusto Ismael Pinto"'
Autor:
Marcela Marinelli Salvadori, Milena Shizue Tariki, Thiago Bueno Oliveira, Aldo Lourenço Abbade Dettino, Flavio Augusto Ismael Pinto, Ana Claudia Machado Urvanegia, Tatiana Vieira Costa, Camila Nassif Martins Ferreira, Christiane Silveira Marinho Albuquerque, José Augusto Rinck, Maria Nirvana Formiga, Marcelo Corassa
Publikováno v:
Journal of Clinical Oncology. 35:525-525
525 Background: TKI have improved the prognosis of patients with mRCC, but rarely lead to durable response. Predictive clinical biomarkers have been studied in the last few years, but most are still controversial. Objective: Identify the role of the
Autor:
Mariana Petaccia de Macedo, Vladmir Cláudio Cordeiro de Lima, Victor Hugo Fonseca de Jesus, Benedito Mauro Rossi, Alexandre Andre Balieiro Anastacio da Costa, Flavio Augusto Ismael Pinto, Maria Dirlei Begnami, Tadeu Ferreira Paiva, Patricia Peresi, Raul Amorim Marques, Ludmilla Thomé Domingos Chinen
Publikováno v:
Journal of Clinical Oncology. 31:11038-11038
11038 Background: There are no validated biomarkers for clinical response or survival benefit in patients treated with bevacizumab (Bv) in advanced metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the predictive value of put
Autor:
Augusto Akikubo Rodrigues Pereira, Flavio Augusto Ismael Pinto, Joyce Maria L. Maia, Celso Lopes Mello, Adriana Regina Gonçalves Ribeiro, Milton Jose De Barros E. Silva, Fernando Vidigal Padua, Daniel Campanha, Marcello Ferretti Fanelli, Tadeu Ferreira Paiva, Elizabeth Santana dos Santos, Ludmilla Thomé Domingos Chinen
Publikováno v:
Journal of Clinical Oncology. 30:e14680-e14680
e14680 Background: Despite the lack of high-quality clinical trial data suggesting that second-line chemotherapy (SLC) may affect survival on metastatic pancreatic cancer (mPC), most of centers utilizes them after the failure of initial treatment in
Autor:
Vladmir Cláudio Cordeiro de Lima, Rafael Costa Lessa, José Augusto Rinck, Sandro José Martins, Marcello Ferretti Fanelli, Augusto Akikubo Rodrigues Pereira, Fernando Vidigal de Pádua, Flavio Augusto Ismael Pinto, Debora de Melo Gagliato, Geraldine Eltz Lima, Marcelo Rocha Cruz, José Rodrigues Pereira, Marclesson S. Alves, Ulisses Ribaldo Nicolau, Paulo Henrique Aires Freitas, Elizabeth Santana dos Santos, Aldo Lourenço Abbade Dettino, Newton Augusto Ferreira Rodrigues
Publikováno v:
Web of Science
e18078 Background: First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with platinum-based doublets, including pemetrexed (P) or bevacizumab (B), has achieved more than 12 months of survival. At the moment, there are no ph
Autor:
Vladmir Cláudio Cordeiro de Lima, Maria Nirvana Formiga, Elzabeth Santana Santos, Debora de Melo Gagliato, Aldo Lourenço Abbade Dettino, Ludmilla Thomé Domingos Chinen, Augusto Akikubo Rodrigues Pereira, Paulo Henrique Aires Freitas, Flavio Augusto Ismael Pinto, Adriana Regina Gonçalves Ribeiro, Victor Hugo Fonseca de Jesus, Marclesson S. Alves, Ulisses Ribaldo Nicolau, Carlos Eduardo Pires Sousa, Joyce Lisboa, José A. Rinck, Newton Augusto Ferreira Rodrigues, Marcello Ferretti Fanelli, Fernando Vidigal Padua
Publikováno v:
Journal of Clinical Oncology. 30:466-466
466 Background: Sunitinib, a multitarget tyrosine-kinase inhibitor, has become a standard of care for first-line low and intermediate risk metastatic renal cell carcinoma (mRCC). Sunitinib-induced hypothyroidism and hypertension have been correlated
Autor:
José Rodrigues Pereira, José Augusto Rinck, Elizabeth Santana dos Santos, C. E. P. Souza, Aldo Lourenço Abbade Dettino, Ludmilla Thomé Domingos Chinen, V. C. C. de Lima, M. F. Fanelli, Ulisses Ribaldo Nicolau, Rafael Costa Lessa, Debora de Melo Gagliato, Marcelo Rocha Cruz, Augusto Akikubo Rodrigues Pereira, Flavio Augusto Ismael Pinto
Publikováno v:
Journal of Clinical Oncology. 29:e18067-e18067
e18067 Background: The combination of pemetrexed plus cisplatin (PC) was recently approved in the initial treatment of advanced stage non-small cell lung cancer (NSCLC). Studies reported comparable...
Autor:
Rafael Costa Lessa, Rafael Malagoli Rocha, Vladmir Cláudio Cordeiro de Lima, Marcello Ferretti Fanelli, Alexandre Andre Balieiro Anastacio da Costa, Felipe D'Almeida Costa, Carlos Eduardo Pires Sousa, Stephania M. Bezerra, Carlos Frederico Lopes Benevides, Paulo Henrique Aires Freitas, Newton Augusto Ferreira Rodrigues, Elizabeth Santana dos Santos, Fernando Vidigal Padua, Debora de Melo Gagliato, Geraldine Eltz Lima, Augusto Akikubo Rodrigues Pereira, Flavio Augusto Ismael Pinto
Publikováno v:
Web of Science
643 Background: Factors predictive of response to anthracyclines can help selecting patients who really benefit from its use. TOP2A (a target of anthracyclines) and HER2 genes are both amplified in 40% of breast cancers. Data from literature are conf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c101f395e409ea9cd1321899ed918755
https://publons.com/wos-op/publon/17669002/
https://publons.com/wos-op/publon/17669002/